Stack

CJC-1295 with DAC

Also known as CJC-1295 DAC

What it is: Long-acting GHRH analog
What it does: Prolongs growth hormone-releasing signaling
Status: Experimental
Evidence: Low. Mostly preclinical and early human research.
Uses: Body composition; GH support research

Caution. Limited clinical evidence; long-acting exposure changes risk profile.

Summary

CJC-1295 with DAC is a GHRH analog fused to a drug-affinity complex that extends half-life, producing sustained GH/IGF-1 elevations. It has been explored in small human studies and experimental protocols for body composition and recovery. Long-acting exposure raises theoretical concerns about tolerance and IGF-1-related risks, and evidence remains early.

Checked Jul 15, 2026.

Keep a record of CJC-1295 with DAC in Stack

Stack logs each dose you take, tracks what is left in the vial or bottle and shows how you kept to your plan. It records what you choose and does not recommend anything. Everything stays on your phone, with no account.

Get Stack on Google Play Peptide reconstitution calculator

More peptides

CJC-1295 without DACExperimental · low evidence IpamorelinExperimental · low evidence NAD+Experimental · moderate evidence SemaxExperimental · low evidence SelankExperimental · low evidence

This entry summarises published information in plain language. It is not medical advice, a dosing recommendation or a substitute for a qualified healthcare professional. Many peptides are not approved for human use, and legal status varies by country. Check anything you rely on against primary sources.